x
[quotes_form]
Request a Quote
Request a Quote

FACT-BMT

Learn More

FACT-BMT form can be integrated into the CS Digital Health app and sent over longitudinal time periods at your discretion and implemented with objective modules to give you unprecedented insight into your patients.

About

FACT-BMT form was designed to measure the QoL in patients undergoing bone marrow transplantation. It combines the FACT-G, an assessment of physical well-being, social/family well-being, emotional well-being and functional well-being, with Bone Marrow Transplantation Sub-scale(BMTS) to measure the QOL of BMT patients. It can be integrated into the Qolty app and sent over longitudinal time periods at your discretion, and implemented with objective modules to give you unprecedented insight into your patients.

Documentation

Introduction

Bone marrow transplantation (BMT) is usually a recommended procedure for patients with cancers (such as Leukemia, Lymphoma, Myelodysplasia, and Multiple Myeloma) and diseases that affect bone marrow cell production (such as Thalassemia). The procedure heavily impacts the quality of life (QOL) of an individual. However, BMT may be the only hope for a cure or a longer life for some individuals.

 

The FACT-BMT was designed to measure the QoL in patients undergoing bone marrow transplantation. It combines the FACT-G, a widely used assessment primarily assessing physical well-being, social/family well-being, emotional well-being, and functional well-being, with Bone Marrow Transplantation Sub-scale(BMTS) to measure BMT specific concerns (McQuellon et al., 1997). Physicians/Oncology nurses with at least 3 years of experience in treating a minimum of 100 BMT patients and patients who had undergone BMT were interviewed in the process of developing BMTS. The interview resulted in the production of 37 candidate questions, of which 12 were selected to represent BMTS in comparison with the FACT-G and to avoid redundancy in combination with the FACT-G questionnaire (McQuellon et al., 1997). Factoring in the newness of the BMT procedures and the significant side effects of the BMT preparative regimens, QoL data of this population is crucial for assessment and rehabilitation processes.

Methods

The FACT-BMT incorporates 12 elements of BMTS and uses a Likert-type scaling ranging from 0 to 4 (where 0 = not at all; 1 = a little bit; 2 = somewhat, 3 = quite; and 4 = very much). The questionnaire is used as a self-assessment and requires the patient to fill it concerning the past 7 days. The FACT-BMT consists of the following categories of assessment:

 

Physical well-being: The patient is asked to rate their physical health regarding sickness, energy, and ability to perform daily activities.

 

Social/family well-being: The patient is asked to rate their social and family environment in relation to emotional support and closure, and other aspects of family and social life.


Emotional well-being: The patient is asked to rate their emotional health regarding mood, anxiousness, and coping skills.


Functional well-being: The patient is asked to rate their functionality in relation to elements of routine and the level of satisfaction with life.


Additional concerns: This category includes other miscellaneous concerns the patient may have concerning their healthcare, persons involved in their life, and other emotions and incapabilities.
The patients are provided with the assessment at three points, once after the BMT (baseline), after hospital discharge, and after 100 days. The frequency of the assessment can be increased as required.

Applications

Multiple Myeloma

Martino et al., 2017 assessed the QoL in patients with multiple myeloma who had undergone autologous stem cell transplantation (ASCT). Based on the patient’s preference for inpatient or outpatient care model, QoL was assessed using FACT-BMT at three points; 7 days before ASCT (Baseline), 7+ days after ASCT and 30+ days after ASCT. Using the FACT-BMT, QoL differences between inpatients and outpatients were compared. Inpatients showed a higher mean score compared to outpatients in physical well-being. However, outpatients showed a higher mean score for social/family well-being in comparison to inpatients.

 

Graft-versus-host disease

Pulewka et al., 2017  focused their attention on graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation (alloHSCT). The study compared QoL assessment through FACT-BMT for adolescent and young adult (AYA) and elderly patients. Assessment comparison revealed that AYA group reported higher physical well-being and activity scores on the FACT-BMT assessment than the non-AYA group.

 

Sexual dysfunction and infertility post-BMT

In a study by Dyer et al., 2016, 421 adult survivors of allogeneic hematopoietic stem cell transplant (HSCT) were surveyed for sexual dysfunction and infertility. The survey showed that females who had returned to sexual activity had significantly higher FACT BMT subscale scores, but did not have any significant differences across other FACT domains.

 

Post-traumatic stress disorder

Hospitalization during hematopoietic stem cell transplantation (HCT) is known to have a deteriorating impact on the QoL of the patients. El-Jawahri’s et al.,2016 study aimed to correlate QoL with the probability of  PTSD in patients hospitalized for HCT. Based on the FACT-BMT assessment, which was carried out pre-transplant (Baseline) and 6 months after the transplant, a decline in QoL was found to be significantly associated with PTSD symptoms in patients after 6 months since HCT. The assessment further highlighted the impact of marital status as a notable predictor of PTSD, as married patients showed fewer symptoms of PTSD after HCT.

 

QoL in the elderly post HCT

Elderly patients with hematologic malignancies are recommended the HCT as the only curative option. In their study, Hamilton et al., 2014 surveyed patients aged 60 and above using FACT-BMT  and compared it with patients aged under 60. Their results showed that there was a significant increase in social well-being and results were comparable in their positivity to patients under the age of 60.

 

Thalassemia

La Nasa’s et al.,  2013 study aimed to investigate the QoL in β-thalassemia major patients who had undergone HSCT. The FACT-BMT assessment was done 20 years after the transplant with the aim to view the difference in health-related QoL of these ex-patients with the general population. The assessment revealed that patients with the confirmed association of GVHD and those with comorbidities or living alone had lower scores of FACT-BMT.

Results and Data Analysis

The following graphs depict sample subscale data of physical well-being and emotional well-being of the FACT-BMT for adolescents (13 to 20 years of age) who underwent the Bone Marrow Transplant Dóro et al., 2003.

Translations

The FACT-BMT assessment is available in a range of different languages

  • Arabic
  • Bengali
  • Bulgarian
  • Chinese (Traditional & Simplified)
  • Croatian
  • Danish
  • Dutch
  • English
  • Farsi
  • Finnish
  • French
  • German
  • Greek
  • Gujarati
  • Hebrew
  • Hindi
  • Hungarian
  • Italian
  • Japanese
  • Kannada
  • Korean
  • Lithuanian
  • Malayalam
  • Marathi
  • Norwegian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Spanish
  • Swedish
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Urdu

The Portuguese translation and validation of the FACT-BMT (Version 3) were done by Mastropietro et al., 2007. Yoo et al., 2006 Korean translated FACT-BMT (Version 4) produced both convergent and divergent validity and a high internal consistency, thus, supporting the Korean version as a valid and reliable measure of QoL for Korean-speaking BMT patients. Lau et al., 2002 produced a culturally sensitive Traditional Chinese FACT-BMT (Version 4) assessment using bilingual teams from the United States and Hong Kong.

Strengths and Limitations

Strengths

BMT preparative regimens can produce significant side-effect, thus, making Fact-BMT assessment crucial for decision making and future treatments. Further, Fact-BMT assessment helps with rehabilitation process initiation and evaluation. These assessments can also be used as indices for future treatments (McQuellon et al., 1997). The FACT-BMT demonstrates validity and reliability and is sensitive to clinically significant change in performance status scores.

Limitations

Similarly, the presence of transplant-specific items on the FACT-BMT limits its use in acute myeloid leukemia (AML) therapies, especially when studies include non-transplant settings (Buckley et al., 2016). The BMTS has a low alpha coefficient when used as a standalone assessment since in encompasses items that share specificity to bone marrow transplantation (McQuellon et al., 1997) and, thus, must never be used alone. However, Fact-BMT overcomes this shortcoming.

Cosmin Checklist

  • The construct validity was analyzed by measuring the correlations between the FACT-BMT domains and the SF-36 Significant correlations were observed between the final FACT-BMT score and all the SF-36 domains (p<0.0001) (Mastropietro et al., 2007)
  • Construct (concurrent) validity was evaluated by examining the inter-scale correlations of the FACT-BMT itself, and their correlation with the SF-36. Most FACT-BMT subscales correlated moderately (r > 0.40) with the SF-36 scales (Lau et al., 2002)
  • FACT-G was developed by Dr. David Cella in 1987.
  • Quality of Life (QoL) “refers to patients’ appraisal of and satisfaction with their current level of functioning compared to what they perceive to be possible or ideal.” (Cella & Cherin 1988).
  • Bone Marrow Transplantation Subscale (BMTS) was developed to address BMT-specific concerns.
  • The FACT-BMT incorporates 12 elements of BMTS and uses a Likert-type scaling ranging from 0 to 4.
  • The FACT-BMT is a patient-reported outcome measure of QoL and is filed concerning the past 7 days.
  • The FACT-BMT assesses patients’ physical well-being, social/family well-being, emotional well-being, functional well-being, and other additional concerns.
  • Assessments are usually performed at three points; once after the BMT (baseline), after hospital discharge, and after 100 days.
  • The BMTS has a low alpha value. However, it is always used in combination with other subscales resulting in high alpha coefficients.
 
 

References

  1. Cella .D.F, Cherin .E.A.(1988) Quality of life during and after cancer treatment. Comprehensive Therapy. 14(5):69- 75.
  2. McQuellon. R.P, Russell .G.B, Cella .D.F…Hurd .D.D (1997). Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplantation. 19(4):357-68.
  3. Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A. (2017). A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biol Blood Marrow Transplant. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021.
  4. Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, Hilgendorf I (2017). Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. J Cancer Res Clin Oncol;143(8):1613-1619. doi: 10.1007/s00432-017-2424-4.
  5. Dyer G, Gilroy N, Bradford J, Brice L, Kabir M, Greenwood M, Larsen SR, Moore J, Hertzberg M, Kwan J, Brown L, Hogg M, Huang G, Tan J, Ward C, Kerridge I. (2016) A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia. Br J Haematol. 172(4):592-601. doi: 10.1111/bjh.13872.
  6. El-Jawahri AR, Vandusen HB, Traeger LN, Fishbein JN, Keenan T, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Spitzer TR, Chen YB, Temel JS (2016). Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. Cancer;122(5):806-12. doi: 10.1002/cncr.29818.
  7. Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA (2014). Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant; 49(11):1426-31. doi: 10.1038/bmt.2014.166.
  8. La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, Sanna M, Marcias M, Littera R, Carcassi C, Lucarelli G. (2013) Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood;;122(13):2262-70. doi: 10.1182/blood-2013-05-502658.
  9. Dóro, M. P., Pasquini, R., & Löhr, S. S. (2003). A functional assessment of adolescents who were recipients of bone marrow transplantation: a prospective study. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842003000100003
  10. Mastropietro AP, Oliveira EA, Santos MA, Voltarelli JC. (2007) Functional Assessment of Cancer Therapy Bone Marrow Transplantation: Portuguese translation and validation. Rev Saude Publicar;41(2):260-8. Portuguese.
  11. Yoo H, Lee K, Lee J, Eremenco S, Choi S, Kim H, Lee J. (2006). Korean translation and validity of FACT-BMT version 4 and the quality of life in allogeneic bone marrow transplantation patients. Qual Life Res;15(3):559-64.
  12. Lau AK, Chang CH, Tai JW, Eremenco S, Liang R, Lie AK, Fong DY, Lau CM. (2002). Translation and validation of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Version 4 quality of life instrument into traditional Chinese. Bone Marrow Transplant;29(1):41-9.

Not sure? Get in touch

Request a Quote

Facebook Twitter Youtube Instagram Reddit-alien

Our Location

Monday – Friday
9 AM – 5 PM EST

Conduct Science

Resources

Support

Customer service

DISCLAIMER: ConductScience and affiliate products are NOT designed for human consumption, testing, or clinical utilization. They are designed for pre-clinical utilization only. Customers purchasing apparatus for the purposes of scientific research or veterinary care affirm adherence to applicable regulatory bodies for the country in which their research or care is conducted.

© Conduct Science 2024